U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Conatus Pharmaceuticals Inc. (CNAT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.38-0.15 (-2.71%)
At close: 4:00PM EDT

5.38 0.00 (0.00%)
After hours: 4:42PM EDT

People also watch
GALTEVOKOCRXAUPHHTBX

Conatus Pharmaceuticals Inc.

16745 West Bernardo Drive
Suite 200
San Diego, CA 92127
United States
858-376-2600
http://www.conatuspharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees25

Key Executives

NameTitlePayExercisedAge
Dr. Steven J. Mento Ph.D.Co-Founder, CEO, Pres & Director835.33kN/A65
Dr. Alfred P. Spada Ph.D.Co-Founder, Chief Scientific Officer and Exec. VP of R&D589.49kN/A59
Dr. David T. Hagerty M.D.Exec. VP of Clinical Devel.590.29kN/A62
Dr. Keith W. Marshall Ph.D., MBACFO, COO & Exec. VPN/AN/AN/A
Mr. Mark F. MorrisHead of BiostatisticsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.

Corporate Governance

Conatus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.